Liquid-liquid phase separation-related gene in gliomas: FABP5 is a potential prognostic marker
The glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required to aid in the evaluation of diagnosis and prognosis. The single cell sequencing dataset scRNA-6148 for glioblastoma was obtained from the Chinese Glio...
Saved in:
Published in | The journal of gene medicine Vol. 25; no. 10; p. e3517 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley Periodicals Inc
01.10.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required to aid in the evaluation of diagnosis and prognosis.
The single cell sequencing dataset scRNA-6148 for glioblastoma was obtained from the Chinese Glioma Genome Atlas database. Data were gathered for the transcriptome sequencing project. Genes involved in liquid-liquid phase separation (LLPS) were taken out of the DrLLPS database. To find the modules connected to LLPS, the weighted co-expression network was analyzed. Differential expression analysis was used to identify the differentially expressed genes (DEGs) in gliomas. Pseudo-time series analysis, gene set enrichment analysis (GSEA) and immune cell infiltration analysis were used to investigate the role of important genes in the immunological microenvironment. We examined the function of key glioma genes using polymerase chain reaction (PCR) testing, CCK-8 assays, clone generation assays, transwell assays and wound healing assays.
FABP5 was identified as a key gene in glioblastoma by multiomics research. Pseudo-time series analysis showed that FABP5 was highly linked with the differentiation of many different types of cells. GSEA revealed that FABP5 was strongly linked to several hallmark pathways in glioblastoma. We looked at immune cell infiltration and discovered a significant link between FABP5, macrophages and T cell follicular helpers. The PCR experiment results demonstrated that FABP5 expression was elevated in glioma samples. Cell experiments showed that FABP5 knockdown dramatically decreased the viability, proliferation, invasion and migration of the LN229 and U87 glioma cell lines.
Our study provides a new biomarker, FABP5, for glioma diagnosis and treatment. |
---|---|
AbstractList | Abstract
Background
The glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required to aid in the evaluation of diagnosis and prognosis.
Methods
The single cell sequencing dataset scRNA‐6148 for glioblastoma was obtained from the Chinese Glioma Genome Atlas database. Data were gathered for the transcriptome sequencing project. Genes involved in liquid–liquid phase separation (LLPS) were taken out of the DrLLPS database. To find the modules connected to LLPS, the weighted co‐expression network was analyzed. Differential expression analysis was used to identify the differentially expressed genes (DEGs) in gliomas. Pseudo‐time series analysis, gene set enrichment analysis (GSEA) and immune cell infiltration analysis were used to investigate the role of important genes in the immunological microenvironment. We examined the function of key glioma genes using polymerase chain reaction (PCR) testing, CCK‐8 assays, clone generation assays, transwell assays and wound healing assays.
Results
FABP5 was identified as a key gene in glioblastoma by multiomics research. Pseudo‐time series analysis showed that FABP5 was highly linked with the differentiation of many different types of cells. GSEA revealed that FABP5 was strongly linked to several hallmark pathways in glioblastoma. We looked at immune cell infiltration and discovered a significant link between FABP5, macrophages and T cell follicular helpers. The PCR experiment results demonstrated that FABP5 expression was elevated in glioma samples. Cell experiments showed that FABP5 knockdown dramatically decreased the viability, proliferation, invasion and migration of the LN229 and U87 glioma cell lines.
Conclusions
Our study provides a new biomarker, FABP5, for glioma diagnosis and treatment. The glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required to aid in the evaluation of diagnosis and prognosis. The single cell sequencing dataset scRNA-6148 for glioblastoma was obtained from the Chinese Glioma Genome Atlas database. Data were gathered for the transcriptome sequencing project. Genes involved in liquid-liquid phase separation (LLPS) were taken out of the DrLLPS database. To find the modules connected to LLPS, the weighted co-expression network was analyzed. Differential expression analysis was used to identify the differentially expressed genes (DEGs) in gliomas. Pseudo-time series analysis, gene set enrichment analysis (GSEA) and immune cell infiltration analysis were used to investigate the role of important genes in the immunological microenvironment. We examined the function of key glioma genes using polymerase chain reaction (PCR) testing, CCK-8 assays, clone generation assays, transwell assays and wound healing assays. FABP5 was identified as a key gene in glioblastoma by multiomics research. Pseudo-time series analysis showed that FABP5 was highly linked with the differentiation of many different types of cells. GSEA revealed that FABP5 was strongly linked to several hallmark pathways in glioblastoma. We looked at immune cell infiltration and discovered a significant link between FABP5, macrophages and T cell follicular helpers. The PCR experiment results demonstrated that FABP5 expression was elevated in glioma samples. Cell experiments showed that FABP5 knockdown dramatically decreased the viability, proliferation, invasion and migration of the LN229 and U87 glioma cell lines. Our study provides a new biomarker, FABP5, for glioma diagnosis and treatment. BackgroundThe glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required to aid in the evaluation of diagnosis and prognosis.MethodsThe single cell sequencing dataset scRNA‐6148 for glioblastoma was obtained from the Chinese Glioma Genome Atlas database. Data were gathered for the transcriptome sequencing project. Genes involved in liquid–liquid phase separation (LLPS) were taken out of the DrLLPS database. To find the modules connected to LLPS, the weighted co‐expression network was analyzed. Differential expression analysis was used to identify the differentially expressed genes (DEGs) in gliomas. Pseudo‐time series analysis, gene set enrichment analysis (GSEA) and immune cell infiltration analysis were used to investigate the role of important genes in the immunological microenvironment. We examined the function of key glioma genes using polymerase chain reaction (PCR) testing, CCK‐8 assays, clone generation assays, transwell assays and wound healing assays.ResultsFABP5 was identified as a key gene in glioblastoma by multiomics research. Pseudo‐time series analysis showed that FABP5 was highly linked with the differentiation of many different types of cells. GSEA revealed that FABP5 was strongly linked to several hallmark pathways in glioblastoma. We looked at immune cell infiltration and discovered a significant link between FABP5, macrophages and T cell follicular helpers. The PCR experiment results demonstrated that FABP5 expression was elevated in glioma samples. Cell experiments showed that FABP5 knockdown dramatically decreased the viability, proliferation, invasion and migration of the LN229 and U87 glioma cell lines.ConclusionsOur study provides a new biomarker, FABP5, for glioma diagnosis and treatment. |
Author | Tang, Qikai Chen, Zhengxin Wang, Zhen Wu, Wei Zhu, Qianmiao Lu, Jiacheng Ma, Chenfeng Zhang, Qixiang Mao, Xiaoman Tu, Yiming |
Author_xml | – sequence: 1 givenname: Qikai surname: Tang fullname: Tang, Qikai organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China – sequence: 2 givenname: Xiaoman surname: Mao fullname: Mao, Xiaoman organization: Department of Neurosurgery, Pukou Branch of Jiangsu People's Hospital, Nanjing Pukou District Central Hospital, Nanjing, China – sequence: 3 givenname: Zhengxin surname: Chen fullname: Chen, Zhengxin organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China – sequence: 4 givenname: Chenfeng surname: Ma fullname: Ma, Chenfeng organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China – sequence: 5 givenname: Yiming surname: Tu fullname: Tu, Yiming organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China – sequence: 6 givenname: Qianmiao surname: Zhu fullname: Zhu, Qianmiao organization: Department of Neurosurgery, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China – sequence: 7 givenname: Jiacheng surname: Lu fullname: Lu, Jiacheng organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China – sequence: 8 givenname: Zhen surname: Wang fullname: Wang, Zhen organization: Department of Orthopaedics, Jinling Hospital, Nanjing Medical University, Nanjing, China – sequence: 9 givenname: Qixiang surname: Zhang fullname: Zhang, Qixiang organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China – sequence: 10 givenname: Wei surname: Wu fullname: Wu, Wei organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37114595$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkEtP3DAUha2KqgO0Er8AWWLTTcDXb7MDVB7SSGVBpa4auZmbwUNiBztZ9N830w4gsTp38eno3O-A7MUUkZAjYKfAGD_brPtTocB8IPugOFScK7k338y5Sjr7c0EOStkwBsZa94kshAGQyql98msZnqewqrp_QYdHX5AWHHz2Y0ixytj5EVd0jRFpiHTdhdT7ck6vLy7vFQ2FejqkEeMYfEeHnNYxlTE0tPf5CfNn8rH1XcEvuzwkP66_PVzdVsvvN3dXF8uqEQBjpbXjYDxq67XQjZdCi9bLlnFjGq2kBi5QgrRoQKMSjeeSuabVqAWzRopD8vV_77zgecIy1n0oDXadj5imUnPLjONSuC168g7dpCnHed1MGWaBK7BvhU1OpWRs6yGH-ac_NbB667yenddb5zN6vCucfve4egVfJIu_lNJ8Aw |
CitedBy_id | crossref_primary_10_1016_j_canlet_2024_216614 |
Cites_doi | 10.1016/j.ncrna.2021.04.003 10.1111/cns.13654 10.1080/14737175.2016.1194755 10.1093/nar/gkz1027 10.1016/j.soncn.2018.10.001 10.7150/thno.44868 10.1007/s11427‐020‐1702‐x 10.1093/neuonc/nou087 10.1016/j.cell.2021.10.001 10.1016/j.drudis.2020.09.018 10.1016/j.devcel.2020.06.033 10.1007/s11910‐013‐0346‐3 10.1016/j.canlet.2020.02.002 10.1093/database/bar026 10.1007/s13311‐017‐0519‐x 10.1158/1078‐0432.CCR‐18‐3626 10.3389/fendo.2021.728088 10.1097/RMR.0000000000000233 10.26355/eurrev_202006_21674 10.1186/1471‐2105‐9‐559 10.1093/nar/gkaa407 10.1016/j.biocel.2017.05.022 10.4103/jcvjs.JCVJS_180_20 10.1007/s10014‐021‐00402‐5 10.1056/NEJMoa1407279 10.1016/j.gpb.2020.10.005 10.1016/j.cancergen.2021.11.001 10.1111/jcmm.16536 10.1093/bioinformatics/bty271 10.1038/s42003‐020‐01367‐5 10.1016/j.nec.2020.09.003 10.1515/revneuro‐2017‐0057 10.1146/annurev‐genet‐112618‐043527 10.3389/fimmu.2022.915709 |
ContentType | Journal Article |
Copyright | 2023 John Wiley & Sons Ltd. 2023 John Wiley & Sons, Ltd. |
Copyright_xml | – notice: 2023 John Wiley & Sons Ltd. – notice: 2023 John Wiley & Sons, Ltd. |
DBID | NPM AAYXX CITATION 7QP 7TK 7TM 8FD FR3 K9. P64 RC3 7X8 |
DOI | 10.1002/jgm.3517 |
DatabaseName | PubMed CrossRef Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef Genetics Abstracts Technology Research Database Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | CrossRef PubMed Genetics Abstracts MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1521-2254 |
EndPage | e3517 |
ExternalDocumentID | 10_1002_jgm_3517 37114595 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Research Project of Jiangsu Health Commission (No. ZD2022054) |
GroupedDBID | --- .3N .GA 05W 0R~ 10A 123 1L6 1OC 29K 33P 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8R4 8R5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BPHCQ BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F D-I DCZOG DPXWK DR2 DRFUL DRMAN DRSTM EBD EBS EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NPM O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 Q2X QB0 QRW R.K ROL RWI RX1 RYL SUPJJ SV3 TEORI UB1 V2E W8V W99 WBKPD WIH WIJ WIK WJL WNSPC WOHZO WQJ WRC WXI WXSBR WYISQ XG1 XV2 ZZTAW ~IA ~WT .55 .Y3 31~ 3V. 7X7 88A 88E 8AO 8FE 8FH 8FI 8FJ AASGY AAYXX ABUWG ACBWZ AFKRA ASPBG AVWKF AZFZN BBNVY BDRZF BENPR BHPHI BVXVI CCPQU CITATION EJD FEDTE FYUFA HCIFZ HF~ HMCUK HVGLF LK8 LW6 M0L M1P M7P PQQKQ PROAC PSQYO UKHRP X7M 7QP 7TK 7TM 8FD FR3 K9. P64 RC3 7X8 |
ID | FETCH-LOGICAL-c311t-669217ae68a636ca4363fa4f0277c6546123e4148e716e53ca2409cf6e6308743 |
ISSN | 1099-498X |
IngestDate | Fri Oct 25 01:55:30 EDT 2024 Thu Oct 10 22:14:52 EDT 2024 Fri Aug 23 02:52:15 EDT 2024 Sat Sep 28 08:16:21 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | glioma immune microenvironment FABP5 liquid-liquid phase separation bioinformatics |
Language | English |
License | 2023 John Wiley & Sons Ltd. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c311t-669217ae68a636ca4363fa4f0277c6546123e4148e716e53ca2409cf6e6308743 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 37114595 |
PQID | 2870812518 |
PQPubID | 42608 |
ParticipantIDs | proquest_miscellaneous_2807924394 proquest_journals_2870812518 crossref_primary_10_1002_jgm_3517 pubmed_primary_37114595 |
PublicationCentury | 2000 |
PublicationDate | 2023-10-01 |
PublicationDateYYYYMMDD | 2023-10-01 |
PublicationDate_xml | – month: 10 year: 2023 text: 2023-10-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Chichester |
PublicationTitle | The journal of gene medicine |
PublicationTitleAlternate | J Gene Med |
PublicationYear | 2023 |
Publisher | Wiley Periodicals Inc |
Publisher_xml | – name: Wiley Periodicals Inc |
References | e_1_2_10_23_1 e_1_2_10_24_1 e_1_2_10_21_1 e_1_2_10_22_1 e_1_2_10_20_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_12_1 e_1_2_10_35_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_34_1 e_1_2_10_10_1 e_1_2_10_33_1 e_1_2_10_11_1 e_1_2_10_32_1 e_1_2_10_31_1 e_1_2_10_30_1 e_1_2_10_29_1 e_1_2_10_27_1 e_1_2_10_28_1 e_1_2_10_25_1 e_1_2_10_26_1 |
References_xml | – ident: e_1_2_10_12_1 doi: 10.1016/j.ncrna.2021.04.003 – ident: e_1_2_10_10_1 doi: 10.1111/cns.13654 – ident: e_1_2_10_23_1 doi: 10.1080/14737175.2016.1194755 – ident: e_1_2_10_18_1 doi: 10.1093/nar/gkz1027 – ident: e_1_2_10_24_1 doi: 10.1016/j.soncn.2018.10.001 – ident: e_1_2_10_31_1 doi: 10.7150/thno.44868 – ident: e_1_2_10_14_1 doi: 10.1007/s11427‐020‐1702‐x – ident: e_1_2_10_2_1 doi: 10.1093/neuonc/nou087 – ident: e_1_2_10_15_1 doi: 10.1016/j.cell.2021.10.001 – ident: e_1_2_10_30_1 doi: 10.1016/j.drudis.2020.09.018 – ident: e_1_2_10_29_1 doi: 10.1016/j.devcel.2020.06.033 – ident: e_1_2_10_5_1 doi: 10.1007/s11910‐013‐0346‐3 – ident: e_1_2_10_4_1 doi: 10.1016/j.canlet.2020.02.002 – ident: e_1_2_10_17_1 doi: 10.1093/database/bar026 – ident: e_1_2_10_3_1 doi: 10.1007/s13311‐017‐0519‐x – ident: e_1_2_10_25_1 doi: 10.1158/1078‐0432.CCR‐18‐3626 – ident: e_1_2_10_9_1 doi: 10.3389/fendo.2021.728088 – ident: e_1_2_10_26_1 doi: 10.1097/RMR.0000000000000233 – ident: e_1_2_10_34_1 doi: 10.26355/eurrev_202006_21674 – ident: e_1_2_10_20_1 doi: 10.1186/1471‐2105‐9‐559 – ident: e_1_2_10_21_1 doi: 10.1093/nar/gkaa407 – ident: e_1_2_10_22_1 doi: 10.1016/j.biocel.2017.05.022 – ident: e_1_2_10_6_1 doi: 10.4103/jcvjs.JCVJS_180_20 – ident: e_1_2_10_28_1 doi: 10.1007/s10014‐021‐00402‐5 – ident: e_1_2_10_7_1 doi: 10.1056/NEJMoa1407279 – ident: e_1_2_10_16_1 doi: 10.1016/j.gpb.2020.10.005 – ident: e_1_2_10_33_1 doi: 10.1016/j.cancergen.2021.11.001 – ident: e_1_2_10_35_1 doi: 10.1111/jcmm.16536 – ident: e_1_2_10_19_1 doi: 10.1093/bioinformatics/bty271 – ident: e_1_2_10_32_1 doi: 10.1038/s42003‐020‐01367‐5 – ident: e_1_2_10_8_1 doi: 10.1016/j.nec.2020.09.003 – ident: e_1_2_10_27_1 doi: 10.1515/revneuro‐2017‐0057 – ident: e_1_2_10_13_1 doi: 10.1146/annurev‐genet‐112618‐043527 – ident: e_1_2_10_11_1 doi: 10.3389/fimmu.2022.915709 |
SSID | ssj0017889 |
Score | 2.4514146 |
Snippet | The glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required to aid in... Abstract Background The glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are... BackgroundThe glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required... BACKGROUNDThe glioma is the most malignant human brain tumor. Early glioma detection and treatment are still difficult. New biomarkers are desperately required... |
SourceID | proquest crossref pubmed |
SourceType | Aggregation Database Index Database |
StartPage | e3517 |
SubjectTerms | Biomarkers Brain cancer Brain tumors Cholecystokinin Diagnosis Gene set enrichment analysis Gene therapy Genes Genomes Glioblastoma Glioma Glioma cells Infiltration Leukocyte migration Lymphocytes T Macrophages Metastases Microenvironments Polymerase chain reaction Time series Transcriptomes Wound healing |
Title | Liquid-liquid phase separation-related gene in gliomas: FABP5 is a potential prognostic marker |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37114595 https://www.proquest.com/docview/2870812518 https://search.proquest.com/docview/2807924394 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKEBIvaHyubCAj8VZltLHjJryNsWpCZQzUShUvkeM6JbAlpR8S8LQ_AYn_cH8Jd7bzUTQQ0Ie0TaNz5fvpfOe7-5mQpxJeqhsqL1EQq3LBuBfx_tQDOxhNueiJKMDm5Ncn4njMX02CSau1bnaXrJJ99e3KvpL_0SrcA71il-w_aLYSCjfgM-gXrqBhuP6VjofZ5zUM6uoV2Jn52pl_gJWps9SW1Rtcu7KewfStgIMJ8gxVyOwsw-og3BQYHLw4DfBwc9mZFyusIMIOrUWBZXhI6XqOVTyLpieL-GrQThiZvybqR24z-m32SWb13rfZnZ1kEgavoHnoukTew_vsS5bXT9uiAJ2n2i2ybo_Cr6vdmpbwFCa-MMmn5WaRJybnPB6ZI4ZhTXKG2O95YGt401LbFukSkd0rVwDLKPtxdr7PAtsVukmyffImHoyHw3h0NBldI9d9sE9YCfjyXcU61uuH5uTE6m-VnMVd_1kpd9OL-U1oYlyU0Ta55WILemCBcpu0dH6H3LCnjX69SxILl8uLHxYo1ACF1kC5vPjuIEJRnTTLqYPIc2oAQrMllbQCCK0BQi1A7pHx4Gh0eOy5IzY8xXq9lSdEBDGp1CKUggklORMslTzFzL7CPjdwbDSHkFlDXK0DpiR4gJFKhRZIJcnZfbKVF7neITScJon2-4oH04SHXZ2wNFUsDDlLopSHqk2elFMWzy2TSmw5s_0YpjXGaW2TvXIuYwfhZYyp-BD98BBEVD-DFcTUlsx1scZnuv3Ixy7vNnlgdVANwvoQ8wdR8PDPwnfJzRq6e2RrtVjrR-BwrpLHBh4_AdNrgto |
link.rule.ids | 315,783,787,27938,27939 |
linkProvider | Wiley-Blackwell |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Liquid%E2%80%93liquid+phase+separation%E2%80%90related+gene+in+gliomas%3A+FABP5+is+a+potential+prognostic+marker&rft.jtitle=The+journal+of+gene+medicine&rft.au=Tang%2C+Qikai&rft.au=Mao%2C+Xiaoman&rft.au=Chen%2C+Zhengxin&rft.au=Ma%2C+Chenfeng&rft.date=2023-10-01&rft.pub=Wiley+Periodicals+Inc&rft.issn=1099-498X&rft.eissn=1521-2254&rft.volume=25&rft.issue=10&rft_id=info:doi/10.1002%2Fjgm.3517&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1099-498X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1099-498X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1099-498X&client=summon |